PRECLINICAL DEVELOPMENT: EARLY CONSIDERATIONS FOR DIFFERENT MOLECULE TYPES
Learn how proper planning and consideration of different molecule types can help you successfully design and conduct your pivotal IND-enabling studies!
IND-enabling studies are required to progress your molecule into the clinic, but there is no one-size-fits-all approach when it comes to designing your program. Though protocol-driven IND-enabling studies are less flexible than efficacy and exploratory studies, there are important program design considerations depending on your specific molecule. Understanding how different molecule types can influence your study can help you anticipate potential issues and avoid unforeseen obstacles that can cost you time and resources.Stream this on-demand webinar as Sinclair Research presents “Preclinical Development: Early Considerations For Different Molecule Types.”
In our webinar, Sinclair Research will help you:
- Considerations when transitioning from discovery to development
- Different molecule types and how they dictate aspects of your IND study
- Standard IND programs for routine small and large molecule classes
- Discover how special molecule classes can impact your study designs
About the Presenter:
Dr. Tina Rogers, PhD, MBA, DABT, is a life sciences executive with 25 years of experience in the CRO industry providing preclinical drug development services to biopharma, NIH and DoD. In her role as Senior Scientific Advisor, Dr. Rogers leads the expansion of Sinclair Research’s nonclinical development services and provides scientific and regulatory guidance to support customer programs. Dr. Rogers holds a PhD in Molecular & Cellular Biology and Pathobiology from the Medical University of South Carolina, an MBA from Auburn University and is a diplomate of the American Board of Toxicology.